Securities Registration: Employee Benefit Plan (s-8)

Date : 04/24/2019 @ 9:29PM
Source : Edgar (US Regulatory)
Stock : Vaxart Inc (VXRT)
Quote : 0.6105  -0.0295 (-4.61%) @ 8:54PM

Securities Registration: Employee Benefit Plan (s-8)

 

 

As filed with the Securities and Exchange Commission on April 24, 2019

Registration No. 3 3 3-                      



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

                            

 

VAXART, INC.  

(Exact name of registrant as specified in its charter)

 

Delaware

 

59-1212264  

(State or other jurisdiction of Incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

290 Utah Ave. , Suite 200

South San Francisco, California 94080

(Address of principal executive offices) (Zip code)

 

                            

 

Vaxart, Inc. 20 19 Equity Incentive Plan

(Full title of the plan)

                            

 

Wouter W. Latour, M.D.

President and Chief Executive Officer

290 Utah Ave. , Suite 200

South San Francisco, California 94080

(650) 550-3522  

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

                            

 

Copies to:

John T. McKenna

Josh Seidenfeld

Cooley LLP

3175 Hanover Street

Palo Alto, CA 94304

(650) 328-4600

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒ 

Smaller reporting company ☒

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities to be Registered

Amount to be Registered ( 1 )

Proposed Maximum

Offering

Price per Share (2)

Proposed Maximum

Aggregate

Offering Price

Amount of

Registration Fee

Common Stock, par value $0.10 per share

       

Vaxart, Inc. 2019 Equity Incentive Plan

1,600,000 shares

$0.76

$1,216,000

$148

 

(1)

Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the 2019 Equity Incentive plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant’s common stock, as applicable.

 

(2)

Estimated in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $0.76 per share, the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market on April 23, 2019.

 

 

 

 

 

 

PART II

 

ITEM 3 .      INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

 

The following documents filed by Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

 

(a)     The Registrant’s Annual Report on Form 10-K (File No. 001-35285) for the year ended December 31, 2018, filed with the SEC on February 6, 2019;

 

(b)     The definitive proxy statement relating to the Registrant’s 2019 annual meeting of stockholders, filed with the SEC on March 11, 2019.

 

(c)     The Registrant’s Current Reports on Form 8-K filed with the SEC on January 18, 2019, March 10, 2019, March 20, 2019, March 27, 2019 and April 24, 2019.

 

(d)     The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 10, filed with the SEC on May 4, 1970, as amended by the Registrant’s Current Report on Form 8-K (File No. 000-04829) filed with the SEC on August 15, 2003.

 

(e)     All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

ITEM 4.     DESCRIPTION OF SECURITIES

 

Not applicable.

 

ITEM 5.       INTERESTS OF NAMED EXPERTS AND COUNSEL

 

Not applicable.

 

ITEM 6.       INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act.

 

The Registrant’s amended and restated certificate of incorporation, as amended, and amended and restated bylaws provide that the Registrant will indemnify its directors and officers, and may indemnify its employees and other agents, to the fullest extent permitted by the Delaware General Corporation Law. However, Delaware law prohibits the Registrant’s certificate of incorporation from limiting the liability of the Registrant’s directors for the following:

 

 

any breach of the director’s duty of loyalty to us or to our stockholders;

 

 

acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

 

 

unlawful payment of dividends or unlawful stock repurchases or redemptions; and

 

 

any transaction from which the director derived an improper personal benefit.

 

 

 

 

The Registrant has entered and expects to continue to enter into agreements to indemnify its directors and officers. These agreements provide for the indemnification of such persons for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were serving in such capacity.

 

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such. The Registrant has obtained director and officer liability insurance to cover liabilities directors and officers may incur in connection with their services to the Registrant.

 

ITEM 7.      EXEMPTION FROM REGISTRATION CLAIMED

 

Not applicable.

 

 

 

 

ITEM 8.      EXHIBITS

 

Exhibit No.

Exhibit Description

Schedule / Form

File Number

Exhibit

Filing Date

 

4.1

 

Amended and Restated Certificate of Incorporation

 

 

10-K

 

001-35285

 

3.1

 

September 13, 2016

4.2

Certificate of Amendment to Restated Certificate of Incorporation of Aviragen Therapeutics, Inc.

 

8-K

001-35285

3.1

February 20, 2018

4.3

Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

 

8-K

001-35285

3.2

February 20, 2018

4.4

Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

 

8-K

001-35285

3.1

April 24, 2019

4.5

Restated Bylaws of Vaxart, Inc.

 

10-K

001-35285

3.2

September 13, 2016

4.6

Form of Common Stock Certificate.

 

S-3

333-228910

4.2

December 20, 2018

5.1*

Opinion of Cooley LLP.

 

       

23.2*

Consent of KPMG LLP, independent registered public accounting firm.

 

       

23.3*

Consent of Cooley LLP (included in Exhibit 5.1)

 

       

24.1*

Power of Attorney (included on the signature page of this Form S-8).

 

       

99.1

Vaxart, Inc. Amended and Restated 2019 Equity Incentive Plan.

 

Form 8-K

001-35285

10.1

April 24, 2019

99.2

Form of Stock Option Grant Notice and Notice of Exercise under the 2019 Equity Incentive Plan.

 

Form 8-K

001-35285

10.2

April 24, 2019

99.3

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan.

 

Form 8-K

001-35285

10.3

April 24, 2019

____________

*Provided herewith.

 

 

ITEM 9.     UNDERTAKINGS

 

1.

The undersigned registrant hereby undertakes:

 

(a)     To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i)     To include any prospectus required by section 10(a)(3) of the Securities Act;

 

(ii)     To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

 

 

 

(iii)     To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

 

Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

 

(b)     That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(c)     To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(d)     That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

(i)     Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

(ii)     Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

(iii)     The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

(iv)     Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

2.     The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

3.     Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on April 24, 2019.

 

 

Vaxart, Inc.

 

 

 

/s/ Wouter W. Latour, M.D.

 

Wouter W. Latour, M.D.

 

President & Chief Executive Officer

 

POWER OF ATTORNEY

 

Know All Persons By These Presents that each person whose signature appears below constitutes and appoints Wouter W. Latour, M.D., and Margaret A. Echerd, each or any one of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature s

Title

Date

 

/s/ Wouter W. Latour , M.D.

Wouter W. Latour, M.D.

 

President, Chief Executive Officer and Director

(Principal Executive Officer and

Principal Financial Officer)

 

April 24, 2019

 

/s/ Margaret A. Echerd

Margaret A. Echerd

 

Vice President, Corporate Controller

(Principal Accounting Officer)

 

April 24, 2019

 

/s/ Richard J. Markham

Richard J. Markham

 

Chairman of the Board

 

April 24, 2019

 

/s/ Michael J. Finney , Ph.D.

Michael J. Finney, Ph.D.

 

Director

 

April 24, 2019

 

/s/ Anne M. VanLent

Anne M. VanLent

 

Director

 

April 24, 2019

 

/s/ Geoffrey F. Cox , Ph.D.

Geoffrey F. Cox, Ph.D.

 

Director

 

April 24, 2019

 

/s/ John P. Richard

John P. Richard

 

Director

 

April 24, 2019

     

 

Vaxart (NASDAQ:VXRT)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more Vaxart Charts.

Vaxart (NASDAQ:VXRT)
Intraday Stock Chart

Today : Thursday 19 September 2019

Click Here for more Vaxart Charts.

Latest VXRT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.